Passardi A.,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori |
Scarpi E.,Unit of Biostatistics and Clinical Trials |
Cavanna L.,Medical Oncology Unit |
Agata M.D.,Unit of Biostatistics and Clinical Trials |
And 11 more authors.
Background: To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal cancer mCRC randomized onto the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) with or without bevacizumab (Bev). Results: In the overall population, PFS and OS were higher in patients with low SII (p = .015 and .002, respectively), low NLR (p = .0001 and <.0001, respectively) and low PLR (p = .004 and .008, respectively). Patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone (HR = 0.69, p = .021). Patients and Methods: Two hundred and eighty-nine patients were considered for this study, 141 receiving CT plus Bev and 148 receiving CT alone. The pre-treatment systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were evaluated to identify a potential correlation with progression-free (PFS) and overall survival (OS) in both the overall population and the 2 treatment arms. Conclusion: Our results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev. Source
Brandes A.A.,Azienda USL IRCCS Institute of Neurological science |
Bartolotti M.,Azienda USL IRCCS Institute of Neurological science |
Marucci G.,University of Bologna |
Ghimenton C.,Verona Hospital |
And 12 more authors.
Critical Reviews in Oncology/Hematology
Medulloblastoma is the most common central nervous system tumor in children, while it is extremely rare in adults. Multimodal treatment involving surgery, radiotherapy and chemotherapy can improve the prognosis of this disease, and recent advances in molecular biology have allowed the identification of molecular subgroups (WNT, SHH, Groups 3 and 4), each of which have different cytogenetic, mutational and gene expression signatures, demographics, histology and prognosis.The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease. © 2014 Elsevier Ireland Ltd. Source
Franceschi E.,Bellaria Hospital IRCCS Institute of Neurological science |
Bartolotti M.,Bellaria Hospital IRCCS Institute of Neurological science |
Brandes A.A.,Bellaria Hospital IRCCS Institute of Neurological science
Recurrent glioblastoma represents a challenge in neuro-oncology since the prognosis is poor and current therapeutic options are limited. Bevacizumab has demonstrated activity in this setting in various clinical trials and has been approved by US FDA for the treatment of recurrent glioblastoma. Nevertheless, many issues still exist. In this article, we summarized the principal subjects of controversies that surround bevacizumab and its use in the treatment of recurrent glioblastoma. © 2015 Future Medicine Ltd. Source
Genestreti G.,Bellaria Hospital IRCCS Institute of Neurological science |
Grossi F.,Unita Operativa Semplice Tumori Polmonari |
Genova C.,Unita Operativa Semplice Tumori Polmonari |
Burgio M.A.,IRST IRCCS |
And 6 more authors.
Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical characteristics and histological and biological features of the disease. In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. Maintenance therapy with pemetrexed and erlotinib resulted in improved progression-free survival compared with second-line therapy at disease progression. In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. Although the benefit of first- and second-line treatment over best supportive care alone has been firmly established, the role of further-line treatment remains controversial. This article summarizes the state-of-the-art treatments in this setting. © 2014 Future Medicine Ltd. Source